论文部分内容阅读
1996年3月22日,本局接到驻亚洲特派情报员负责人“三上真司”的最高机密报告书。报告书中提到有一定非证实情报表明,目前国际性制药集团——安布雷拉(UMBRELLA)有正在从事非法生化武器研究工作的迹象。对此本局极为关注,安排本局秘密部门“对生化危机事件(BIOHAZARD)对策部门”的特别调查员进行初步调查工作。因为安布雷拉制药集团董事会由欧洲名声显赫的贵族组建,并拥有众多药物的独占专利,再加上集团内部制度森严,所以调查员在没有绝对证据的情况下无法实施正式调查工作,而秘密调查员的潜入工作也异常困难。以下为从1996年立案开始至1998年8月初的调查备忘录——
On March 22, 1996, this Council received the top-secret confidential report of the chief of the special intelligence service for Asia “Shinsengumi”. Some non-substantiated intelligence mentioned in the report shows that there is now evidence that UMBRELLA, an international pharmaceutical group, is engaged in research on illegal biological and chemical weapons. In this regard, this Council is extremely concerned about the preliminary investigation carried out by the secret department of this Council and the special investigators on the “BiOHAZARD countermeasures department”. Because the Board of Ambre Pharmaceuticals is formed by a prominent European aristocracy and owns a number of monopoly patents for drugs, combined with the internal system of the group, investigators can not conduct formal investigations without absolute evidence, and clandestine investigations Squad work is also extremely difficult. The following is a memo from the beginning of the case in 1996 to the beginning of August 1998: